U.S., March 12 -- ClinicalTrials.gov registry received information related to the study (NCT07463235) titled 'Safety and Potency of a High Cabergoline Dosage in Microprolactinomas' on March 04.
Brief Summary: This will be a multicenter, prospective, randomized, open-label trial with women harboring microprolactinomas and treatment naive. The sample will be added consecutively and randomized into 2 unblinded groups: the high dosage group will receive a high cabergoline (CAB) dose for a period of ~6 months vs the standard dosage group, which will use the lowest needed dose of CAB to achieve normoprolactinemia for 2 years. The primary outcome will be remission rate.
Study Start Date: March 04
Study Type: INTERVENTIONAL
Condition:
Prolacti...